All Blogs

Oct 24, 2024

iRhythm Technologies Received FDA 510(k) Clearance for Design Updates Previously Made to Its Zio® AT Device  On October 21, 2024, iRhythm Technologies, Inc., a leading digital healthcare company specializing in solutions to detect, predict, and prevent disease, announced that the U.S. Food and Drug Administ...

Oct 23, 2024

Plasma protein therapeutics are revolutionizing the landscape of modern medicine by harnessing the healing potential of the human body. Derived from donated blood plasma, these life-saving treatments are packed with antibodies, clotting factors, and other essential proteins that help manage a wide array of conditio...

Oct 22, 2024

Gilead and Merck Reports Phase II Data Showing that Switching to a Once-Weekly Oral Combination of Islatravir and Lenacapavir Maintained Viral Suppression in Adults Through 48 Weeks Gilead Sciences, Inc. and Merck have shared new findings from a Phase II clinical trial assessing the experimental combination of i...

Oct 21, 2024

Exosomes are tiny, powerful messengers that are revolutionizing the way we think about communication between cells. These nanosized vesicles carry crucial signals—proteins, lipids, and RNA—between cells, playing a pivotal role in everything from immune responses to tissue repair. What makes exosomes truly exciting ...

Oct 18, 2024

In the ever-evolving world of liver disease, the shift from Nonalcoholic Steatohepatitis (NASH) to Metabolic Associated Steatotic Hepatitis (MASH) marks a revolutionary leap in our understanding and approach to treatment. This transition isn't merely a rebranding; it signifies a profound recognition of the intricat...

Oct 17, 2024

FDA Approved Roche’s Itovebi, a Targeted Treatment for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation  On October 11, 2024, Roche announced that the United States Food and Drug Administration (FDA) approved Itovebi™ (inavolisib), in combination with palbociclib (Ibran...

Oct 16, 2024

Pompe disease is a rare genetic disorder that presents a spectrum of severity, with varying rates of progression and ages of onset. Symptoms can appear anywhere from infancy to late adulthood, with earlier onset generally associated with more rapid progression and increased severity. At all ages, the disease is mar...

Oct 15, 2024

Astellas & AviadoBio Sign Exclusive Deal for Gene Therapy AVB-101 in Frontotemporal Dementia AviadoBio Ltd. and Astellas Pharma Inc. have announced a strategic partnership under an exclusive option and license agreement for AVB-101, an investigational AAV-based gene therapy currently in Phase I/II developmen...

Oct 14, 2024

At present, REZDIFFRA stands as the only approved NASH drug to battle the devastating disease. This once-daily, oral THR-β agonist received a fast-track nod from the US FDA in March 2024, thanks to the impressive outcomes of the Phase III MAESTRO-NASH trial. But with one trailblazer already in the ring, the race is...

Oct 11, 2024

Prostate cancer is one of the most common cancers among men, affecting about 1 in 8 men in the United States at some point in their lives. According to estimates from DelveInsight, there were nearly 8.2 million total cases of prostate cancer in the 7MM in 2023, although this number does not indicate how many of the...